Someone must be noticing THTXJust looking at the trading since the post offering low and comparing it to the pre offering levels, it does appear there is a decent stealthy accumulation of shares going on from this 2.20 on up levels (last 8 days or so). Previous to deal, volume was around 100k shares a day, now it's average 300k or more the last week which is post the deal puke and in this uptrend. I'm looking at the NASDAQ listing stats. Seems willing to move it up to get volume which is nice to see. Maybe we'll get back to that darn $3 handle sooner than any of us thought. Would be a nice development pre the AACR conference.
The previous PR mentioned they would present new in vivo data in the 4 cancers they've mentioned and that they added to the IND Phase 1 trial. The PR just states the in vivo data "confirms" it works on them and mentions new data on dosage and tolerability.
The one other thing it mentions that is not in the trial is melanoma and I think Marsolais mentioned that at the BRiley conference as something they were testing now. It has SORT1 > 90% overexpressed. I've never seen anything on that. Just put it out there that we still need to hear if it worked well on that indication and that maybe they'll add that one as a fifth indication to go after in this first trial. Right now they have specified 10 people per arm in the 4 indications they're going for with TH1902 (TNBC, Ovarian, Colorectal, Pancreatic). Anyway, at some point I suppose we should hear something on this melanoma data. It's not mentioned as one they will be presenting at the AACR but maybe they'll add that in as a surprise.